SGLT2 inhibition reduces myocardial oxygen consumption

Esben Søndergaard1,2, Esben S Lauritzen1, Katrine M Lauritsen1,2

  • 1Steno Diabetes Center, Aarhus, Denmark.

Metabolism Open
|September 12, 2022
PubMed

Insights

Sodium-glucose cotransporter 2 (SGLT2) inhibition reduces myocardial oxygen consumption. This finding may explain the cardioprotective effects of SGLT2 inhibitors in patients with cardiac disease.

Area of Science:

  • Cardiology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Sodium-glucose cotransporter 2 (SGLT2) inhibition is linked to reduced cardiac disease risk, but mechanisms remain unclear.
  • Improved myocardial energetics is a proposed explanation for the cardioprotective effects of SGLT2 inhibitors.
  • Previous studies lacked the statistical power to confirm these effects.

Purpose of the Study:

  • To investigate the impact of SGLT2 inhibition on myocardial oxygen consumption and external efficiency.
  • To leverage pooled data from randomized clinical trials for enhanced statistical power.

Main Methods:

  • Meta-analysis of data from two randomized clinical trials.
  • Measurement of myocardial oxygen consumption and external efficiency using positron emission tomography.
  • Analysis included 59 participants.

Main Results:

  • SGLT2 inhibition significantly reduced myocardial oxygen consumption ( -1.06 mL/100g/min; p=0.01).
  • No significant effect was observed on myocardial external efficiency (p=0.13).

Conclusions:

  • SGLT2 inhibition decreases resting myocardial oxygen consumption.
  • This reduction in oxygen demand may contribute to the observed cardioprotective benefits of SGLT2 inhibitors.
Abstract